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Abstract
Introduction: Type 17 T helper cells and interleukin (IL)-17 play important roles in the pathogenesis of human and
murine arthritis. Although there is a clear link between IL-17 and granulocyte macrophage colony-stimulating factor
(GM-CSF) in the inflammatory cascade, details about their interaction in arthritic synovial joints are unclear. In view
of the introduction of GM-CSF and IL-17 inhibitors to the clinic, we studied how IL-17 and GM-CSF orchestrate the
local production of inflammatory mediators during experimental arthritis.
Methods: To allow detection of additive, complementary or synergistic effects of IL-17 and GM-CSF, we used two
opposing experimental approaches: treatment of arthritic mice with neutralising antibodies to IL-17 and GM-CSF
and local overexpression of these cytokines in naive synovial joints. Mice were treated for 2 weeks with antibodies
against IL-17 and/or GM-CSF after onset of collagen-induced arthritis. Naive mice were injected intraarticularly with
adenoviral vectors for IL-17 and/or GM-CSF, resulting in local overexpression. Joint inflammation was monitored
by macroscopic scoring, X-rays and histology. Joint washouts, synovial cell and lymph node cultures were analysed
for cytokines, chemokines and inflammatory mediators by Luminex analysis, flow cytometry and quantitative
polymerase chain reaction.
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Results: Combined therapeutic anti-IL-17 and anti-GM-CSF ameliorated arthritis progression, and joint damage was
dramatically reduced compared with treatment with anti-IL-17 or anti-GM-CSF alone. Anti-IL-17 specifically reduced
synovial IL-23 transcription, whereas anti-GM-CSF reduced transcription of matrix metalloproteinases (MMPs) and
receptor activator of nuclear factor κB ligand (RANKL). Overexpression of IL-17 or GM-CSF in naive knee joints
elicited extensive inflammatory infiltrate, cartilage damage and bone destruction. Combined overexpression
revealed additive and synergistic effects on the production of MMPs, RANKL and IL-23 in the synovium and led to
complete destruction of the joint structure within 7 days.
Conclusions: IL-17 and GM-CSF differentially mediate the inflammatory process in arthritic joints and show
complementary and local additive effects. Combined blockade in arthritic mice reduced joint damage not only by
direct inhibition of IL-17 and GM-CSF but also by indirect inhibition of IL-23 and RANKL. Our results provide a
rationale for combination therapy in autoinflammatory conditions, especially for patients who do not fully respond
to inhibition of the separate cytokines.
Introduction
Rheumatoid arthritis (RA) is a systemic disease charac-
terized by chronic inflammation of synovial joints. The
aetiology of RA remains unclear, but the pathogenesis
has been studied extensively in patients as well as in
animal models [1, 2]. In RA, inflammatory cells such as
neutrophils, natural killer cells and T and B lympho-
cytes infiltrate the synovial membrane, contributing to
bone and cartilage degradation. Of the T cells in the in-
flamed synovium, CD4+ T cells are the most abundant.
CD4+ T cells can differentiate into type 1 T helper
(Th1), Th2, Th17 or regulatory T cells, depending on
the local cytokine milieu [3]. Originally, RA was classified
as a Th1-mediated disease, but it is now well established
that Th17 cells play a crucial role in RA pathogenesis
(reviewed in [4]).
Th17 cells are important mediators of inflammatory
disease and are identified by the production of interleu-
kin (IL)-17 [5, 6]. Th17 cells are the main pathogenic cell
type in many models of autoimmunity, including experi-
mental autoimmune encephalomyelitis (EAE) [7], acute
inflammatory arthritis [methylated bovine serum albumin
(mBSA)/IL-1β] arthritis) [8] and collagen-induced arthritis
(CIA) [9]. Pathogenic Th17 cells have also been identified
in inflamed synovia of patients with RA [10]. Neutralisa-
tion of IL-17 during CIA showed that IL-17 plays a direct
and indirect role in joint inflammation and joint destruc-
tion [11, 12]. IL-17 receptor–deficient mice show reduced
sensitivity to inflammation [13].
Recent data illustrate that granulocyte macrophage
colony-stimulating factor (GM-CSF) plays a crucial role
in mediating T cell function in inflammatory conditions.
IL-23 is required for functional maturation and patho-
genicity of Th17 cells via RAR-related orphan receptor
γt (RORγt)-mediated induction of GM-CSF production
[14–17]. GM-CSF in turn also induces IL-23 production
by dendritic cells (DCs) via CC chemokine receptor 4
(CCR4), thereby creating a positive feedback loop for the
production of these two cytokines [18]. Interestingly, GM-
CSF-deficient mice are resistant to many Th17-dependent
models of autoimmune disease, including CIA, mBSA/IL-
1β, EAE and experimental autoimmune myocarditis
[8, 19–21], and GM-CSF-deficient Th17 cells are unable
to induce EAE upon adoptive transfer [16]. GM-CSF-
producing T cells were detected in synovial fluid taken
from patients with juvenile idiopathic arthritis, and Th17
cells from these patients rapidly upregulated GM-CSF
production in culture [22]. In addition, NF-κB1-deficient
mice, which have a relatively selective defect in GM-
CSF production by T cells, were protected from acute
inflammatory arthritis and peritonitis [23]. Mice that
overexpress GM-CSF specifically in T cells have in-
creased Th17-related cytokines in the serum [24].
Although there is no doubt that both IL-17 and GM-
CSF play indispensable roles in the pathogenesis of RA,
the question remains what the interplay is between these
cytokines. In the present study, we used two opposing
approaches to address this question: (1) by combined
neutralisation of GM-CSF and IL-17 during established
CIA and (2) by combined local adenoviral overexpression
of GM-CSF and IL-17 in the knee joint. Our results pro-
vide a rationale for combined neutralisation of GM-CSF
and IL-17 in autoinflammatory conditions such as RA.
Methods
Mice
Eight- to ten-week-old male DBA/1 J mice (Janvier Labs,
Saint Berthevin, France) were allowed to acclimatize for
a minimum of 7 days in the Central Animal Laboratory of
the Radboud University Medical Centre. The animals were
kept in conventional filter-top cages (for the neutralisation
experiment) or in specialised individually ventilated cages
(for the adenoviral overexpression experiment). A max-
imum of 11 animals were kept in each cage. Food and
water was provided ad libitum, and mice were subjected
to 12-hour cycles of light and darkness.
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All animal experiments were approved by the ethics
committee of Radboud University Nijmegen (approval
number 2013–042).
Induction of arthritis
CIA was induced as previously described [25]. Joint in-
flammation was scored macroscopically in each paw
using a scale of 0–2, where 0 = not inflamed, 1 = mild,
1.5 = marked and 2 = severe. Scoring was performed by a
researcher blinded to the experimental groups. From day
21, mice were scored three times weekly and randomly
divided over the treatment groups once the arthritis
score reached between 0.25 and 1.25.
Antibody treatment
Mice received intraperitoneal injections of anti-IL-
17 (100 μg/mouse, clone MAB421; R&D Systems,
Minneapolis, MN, USA), anti-GM-CSF (200 μg/mouse,
clone 22E9; kind gift from Micromet AG, München,
Germany), or isotype control antibody [300 μg/mouse, rat
immunoglobulin G (IgG)] three times weekly from the on-
set of disease. The total duration of treatment for each
mouse was 14 days.
Adenoviral vectors
The adenoviral expression vector for murine IL-17A
(Ad-IL-17) was kindly provided by Dr. J. K. Kolls (Chil-
dren’s Hospital of Pittsburgh, Pittsburgh, PA, USA). The
adenoviral expression vector for murine GM-CSF (Ad-
GM-CSF) was provided by RIKEN BioResource Centre
(Tsukuba, Japan), which is participating in the National
BioResource Project of the MEXT (Ministry of Education,
Culture, Sports, Science, and Technology, Tokyo, Japan).
An adenoviral expression vector for luciferase (Ad-LUC)
generated in-house was used as a control vector through-
out the study. Virus titres [in focus forming units (ffu) per
millilitre] were determined by performing focus forming
assays as described previously [26].
Intraarticular injection of adenoviral vectors
Mice received intraarticular injections of 6 μl of virus
suspension in phosphate-buffered saline. For the groups
treated with Ad-GM-CSF or Ad-IL-17 alone, 0.5 × 107
ffu of the respective vectors was injected, supplemented
with 0.5 × 107 ffu of the control vector, Ad-LUC. For the
group receiving both Ad-GM-CSF and Ad-IL-17, 0.5 ×
107 ffu of each vector was injected. Knee joints were
harvested at 4 h and days 1, 4 and 7 after injection for
analysis.
RNA purification and quantitative real-time PCR
mRNA from synovial tissue was purified using TRIzol
reagent (Sigma-Aldrich, St. Louis, MO, USA) and MagNA
Lyser beads (Roche Diagnostics, Mannheim, Germany)
according to the manufacturers’ instructions. cDNA was
obtained by reverse transcription. Quantitative real-time
PCR (qPCR) was performed using the ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) for quantification with SYBR Green
(Molecular Probes; Life Technologies, Carlsbad, CA,
USA) and melting curve analysis. Fold increases of
mRNA transcripts were calculated as follows: ΔCt = Ct
(gene of interest) − Ct (glyceraldehyde 3-phosphate de-
hydrogenase), ΔΔCt = ΔCt sample − average ΔCt control
group, and fold difference = 2−ΔΔCt.
Patella washouts
Patellae, including attached synovial tissue, were re-
moved from the knee joints and cultured in 200 μl of
RPMI medium supplemented with 10 % foetal bovine
serum for 1 h at room temperature. Supernatants were
harvested for cytokine measurement.
Flow cytometry
Single-cell suspensions from synovial tissue were pre-
pared as described previously [27]. Synovial cells were
stimulated in the short term (3–4 h) with phorbol 12-
myristate 13-acetate (50 ng/mL) and ionomycin (1 μg/ml)
before analysis to allow recovery of the cells after tissue di-
gestion. Antibodies used were anti-CD4 Alexa Fluor 700
(clone GK1.5) and anti-CD8-PerCp (clone 53–6.7) (both
from BioLegend, San Diego, CA, USA). All samples were
measured on a CyAn ADP instrument (Beckman Coulter,
Brea, CA, USA) and analysed using FlowJo software
(FlowJo, Ashland, OR, USA).
Measurement of cytokines and chemokines
Cytokines and chemokines were measured by Luminex
technology according to the manufacturer’s instructions
(EMD Millipore, Billerica, MA, USA). The results were
analysed using BioPlex Manager 4 (Bio-Rad Laborator-
ies, Hercules, CA, USA).
Measurement of collagen-specific IgG in serum
Anti-collagen IgG1 and IgG2a antibody titres against bo-
vine type II collagen (CII) were determined by enzyme-
linked immunosorbent assay as described previously [11].
X-ray analysis of ankle joints
X-rays from ankle joints were taken using a Faxitron
MX20 instrument (Faxitron Bioptics, Tucson, AZ, USA)
and analysed using Faxitron software.
Histology
Joints were fixed for 4 days in 10 % formalin and decal-
cified in 5 % formic acid, and then they were embedded
in paraffin. Seven-micrometre sections were stained with
haematoxylin and eosin (H&E) or Safranin O (SafO).
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Inflammation, chondrocyte death, bone destruction, car-
tilage damage and proteoglycan (PG) depletion were
scored on a scale of 0–3 by a researcher blinded to the
experimental groups.
Statistical analysis
Statistical significance was calculated using the Prism 6
software package (GraphPad Software, La Jolla, CA, USA)
by one- or two-way analysis of variance, followed by
Bonferroni’s multiple-comparisons test. p values <0.05
were considered significant.
Results
Combined neutralisation of GM-CSF and IL-17 blocks
progression of CIA
CIA was induced, and antibody treatment was started
from the onset of disease. Mice that received the control
antibody developed severe arthritis, reaching a macro-
scopic disease severity score of 5.55 ± 0.38 after 2 weeks
of treatment (Fig. 1a). In contrast, a significant reduction
in arthritis severity was observed after treatment with
anti-IL-17 or anti-GM-CSF, resulting in endpoint scores
of 3.4 ± 0.4 and 3.5 ± 0.4, respectively. Combination treat-
ment completely ameliorated disease progression and re-
sulted in a score of 2.0 ± 0.6 after 2 weeks of treatment.
These effects were dose-dependent, with suboptimal
combination therapy (30 μg of anti-IL-17 + 100 μg of anti-
GM-CSF) reaching an end score of 3.9 ± 0.5, and subopti-
mal therapy with either antibody alone, resulting in end
scores of 4.9 ± 0.4 for anti-GM-CSF and 3.5 ± 0.4 for anti-
IL-17, respectively (data not shown). This result illustrates
the additive beneficial effect of combined IL-17/GM-CSF
neutralisation.
Combined neutralisation of GM-CSF and IL-17 protects
against bone and cartilage damage
Ankle joints were subjected to X-ray analysis to visualise
bone destruction and changes in joint morphology
(Fig. 1b, c). Bone damage in the small joints of the ankle
and foot was observed in animals treated with anti-IL-17
or anti-GM-CSF alone (Fig. 1c), consistent with the
macroscopic arthritis scores. Mice treated with the control
antibody showed severe distortion of joint morphology
and extensive bone damage (Fig. 1b, c). In contrast, most
animals treated with a combination of anti-IL-17 and anti-
GM-CSF showed near-normal joint morphology and
minor or no bone degradation, although overall the
average Faxitron scores were not significantly different be-
tween the groups (Fig. 1b, c). Other features of joint path-
ology were scored by histology on H&E- and SafO-
stained, paraffin-embedded sections (Fig. 1d, e, f ). Com-
bination therapy resulted in a marked reduction of each
feature scored (Fig. 1e) and was more effective than treat-
ment with the separate antibodies (Fig. 1e, f ).
Differential local and systemic effects on inflammatory
mediators by blockade of IL-17 or GM-CSF
Local production of cytokines and chemokines was mea-
sured in joint washouts. The major cytokines produced
by arthritic synoviocytes were IL-6, chemokine (C-X-C
motif) ligand 1 (CXCL1), CC chemokine ligand 2 (CCL2)
and CCL3 (Fig. 2a). The production of IL-6 was not af-
fected in mice treated with anti-IL-17 or anti-GM-CSF
alone; however, combination treatment led to a significant
increase in this cytokine compared with the other treat-
ment groups (Fig. 2a). This is most likely due to the re-
duced influx of IL-6 receptor-expressing naive CD4+ T
cells and the absence of inflammatory cells and osteoclasts
in the joints of these mice, resulting in reduced consump-
tion of IL-6 [4, 28]. Production of CXCL1, CCL2 and
CCL3 was not affected by antibody treatment. In agree-
ment with earlier studies, tumour necrosis factor (TNF)
was not detected in the joint washouts [29, 30] (data not
shown). Synovial cells were also analysed by flow cytome-
try to detect infiltrating CD4+ T cells. Anti-GM-CSF treat-
ment and combination treatment resulted in a slight
reduction of infiltrating CD4+ T cells. This effect was not
observed in the mice treated with anti-IL-17 (Fig. 2b, c).
The systemic effect of antibody treatment was deter-
mined by analysis of serum cytokines. The level of IL-6
was significantly decreased in the antibody-treated ani-
mals, which is in agreement with recent data from clin-
ical trials of GM-CSF inhibitors in RA [31] and previous
data from our laboratory [12]. There was no difference
between treatment groups (Fig. 2d). No other arthritis-
related cytokines [IL-1β, TNF, IL-17, interferon-γ, IL-4,
CCL5 (also called RANTES, for regulated on activation,
normal T cell expressed and secreted) and GM-CSF]
could be detected in the serum (data not shown). To as-
sess the effect of GM-CSF or IL-17 blockade on the pro-
duction of anti-collagen antibodies, collagen-specific IgG
was measured in serum. A reduction in total CII-specific
IgG was seen in the mice receiving anti-GM-CSF treat-
ment, but it did not reach statistical significance (Fig. 2e).
Neutralisation of granulocyte macrophage
colony-stimulating factor, but not interleukin-17, inhibits
production of matrix metalloproteinases
Cartilage and bone degradation are partly mediated by
matrix metalloproteinases (MMPs) and alarmins, such
as S100A8 [32, 33] and tissue inhibitors of metallopro-
teinase (TIMPs) [32]. The synovial expression of these
and several T cell and DC/macrophage-related mediators
was determined by qPCR (Table 1). We found a pro-
found reduction in MMPs after GM-CSF neutralisation
and a decrease in Th17-related factors GM-CSF, RORγt
and IL-21. IL-17 mRNA was not detected in the anti-
GM-CSF samples, but, interestingly, the expression of
IL-23 was not different from that in the control group.
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Fig. 1 Neutralisation of interleukin (IL)-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) during established collagen-induced
arthritis (CIA). a Macroscopic disease scores followed over time from day 21 (day 0 of treatment). n = 10 mice/group. Arrows indicate times of
antibody treatment. p values were calculated by two-way analysis of variance (ANOVA) after calculation of the area under the curve. b Endpoint
X-ray analysis of ankle joints after CIA. Representative ankle joint shown for the isotype control and the anti-IL-17 + anti-GM-CSF groups. c Pooled
endpoint X-ray analysis of ankle joints scored for bone damage [n = 20 joints/group; mean ± standard error of the mean (SEM)]. d Histological
analysis of ankle joints. Original magnification, ×50. e Detailed histological scores of the ankle joints after 14 days of treatment. n = 20 joints/group.
f Total histological scores. n = 20 joints/group. Mean ± SEM. *p < 0.05; ***p < 0.001; ****p < 0.0001, two-way ANOVA and Bonferroni’s test for
multiple comparisons. H&E haematoxylin and eosin, NS not significant, PG proteoglycan, SafO safranin O stain
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Although anti-IL-17 treatment had a clear effect on joint
damage, it was not reflected in the levels of MMP or
TIMP mRNA in the joints of these mice. However, we
also found a reduction in the level of the Th17-related
factors RORγt, IL-21 and IL-23. Combination therapy
led to an overall downregulation of MMPs. The effect
on TIMP expression was modest in all treatment groups.
Interestingly, IL-1β and IL-23 were upregulated after
Fig. 2 Cytokines in synovial washouts and serum and flow cytometric analysis of synovium and serum immunoglobulin G (IgG) after 14 days of
interleukin (IL)-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) blockade. a Luminex analysis of cytokines and chemokines in
joint washouts (n = 6 mice per group). b Flow cytometric analysis of phorbol 12-myristate 13-acetate/ionomycin-stimulated synovial tissue stained
with monoclonal antibodies for CD4 and CD8 after 14 days of treatment. The gate depicts the percentage of CD4+ cells of single synoviocytes.
Plots shown are representative of n = 6 joints/group. Mean ± standard error of the mean (SEM) for each group is given in the fluorescence-activated
cell sorting plot. c Summary graph for the flow cytometric analysis of synovial tissue. Box depicts 25th to 75th percentiles. Line depicts median. Whiskers
depict minimal to maximal values. n = 6 mice per group. d IL-6 levels in serum measured by Luminex assay. n = 10 mice/group. Mean ± SEM. e Total
collagen-specific immunoglobulin G (IgG) in serum. n = 7–10 mice/group. *p < 0.05; **p < 0.01; analysis of variance followed by Bonferroni’s test
for multiple comparisons. CCL CC chemokine ligand, CII type II collagen, CXCL chemokine (C-X-C motif) ligand, KC keratinocyte, MCP monocyte
chemoattractant protein, MIP macrophage inflammatory protein, NS not significant
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combined neutralisation (Table 1). This is most likely
due to a reduction in consumption of these factors,
owing to the lack of infiltrating inflammatory cells.
Overexpression of GM-CSF and IL-17 in the knee joint
leads to joint destruction
Our second approach to studying the IL-17–GM-CSF
interaction was local overexpression in naive murine
knee joints. Injection with Ad-IL-17 caused a mild inflam-
matory reaction in the joint on day 4, which increased to
severe on day 7, when moderate to severe bone erosion
and PG depletion were apparent (Fig. 3a–e). In contrast,
Ad-GM-CSF injection led to severe synovitis and exudate
on day 4, with increased bone erosion, PG depletion and
cartilage damage on day 7. Injection with Ad-IL-17 + Ad-
GM-CSF caused accelerated joint damage, with severe
inflammation, bone erosion and PG depletion on day 4.
Normal joint architecture was lost by day 7 owing to ex-
tensive inflammation (Fig. 3a), which suggested additive
effects of these cytokines. Mice that received injections
with the control vector Ad-LUC showed mild inflam-
mation early after injection, but this resolved within
7 days.
Combined expression of GM-CSF and IL-17 induces
CXCL1, IL-6, IL-23, RANKL and MMPs in synovial tissue
The expression of inflammatory cytokines, RORγt and
MMPs was measured in synovial tissue by qPCR and
Luminex analysis at 4 h, 1 day and 4 days after adenoviral
transfer (Figs. 4 and 5). Increased transcription of IL-17A
and GM-CSF in the mice transferred with the respective
adenoviral vectors was confirmed by qPCR (Fig. 4a). Tran-
scription levels were similar between the two cytokines
(measuring a 103 to 104 increase over the control group
transfected with Ad-LUC), and they remained at this level
for at least 4 days after transfer. IL-17 mRNA began to de-
crease at day 4 in the mice transfected with Ad-IL-17 only;
in mice that received both Ad-IL-17 and Ad-GM-CSF,
transcription remained high. We did not detect any syner-
gism at the transcriptional level between the cytokines in
the mice injected with both vectors. Interestingly, the
transcription of RORγt was increased in all groups on day
4, suggesting that Th17 differentiation in the joints was in-
duced by the presence of IL-17 as well as GM-CSF
(Fig. 4a). IL-23 increased on day 4 for the Ad-IL-17 group
(Fig. 4a), but overexpression of GM-CSF induced IL-23
production earlier, in keeping with the relationship
Table 1 Quantitative PCR of synovial tissue after 2 weeks of antibody treatment during collagen-induced arthritis (fold increase over
isotype control-treated samples (2−ΔΔCt)
Gene Anti-IL-17 Anti-GM-CSF Anti-IL-17 + anti-GM-CSF
Damaging Proinflammatory T cell factors IL-17A 1.63 ± 0.56 not detected 1.48 ± 1.0
GM-CSF 1.12 ± 0.73 0.55 ± 0.54 0.55 ± 0.2
RORγt 5.06 ± 2.94a,b 0.68 ± 0.30c 1.68 ± 0.96c
IL-21 2.30 ± 1.14 0.88 ± 0.61 0.71 ± 0.35
RANKL 0.97 ± 0.49 0.36 ± 0.19 0.80 ± 0.56
Matrix metalloproteinases MMP3 0.87 ± 0.45 0.24 ± 0.10 0.51 ± 0.26
MMP9 1.18 ± 0.71 0.36 ± 0.18 0.75 ± 0.42
MMP13 0.89 ± 0.38 0.44 ± 0.18 0.60 ± 0.31
MMP14 1.43 ± 0.55 0.58 ± 0.22 0.74 ± 0.32
ADAMTS5 1.34 ± 0.67 0.43 ± 0.24 0.89 ± 0.50
Alarmin S100A8 1.82 ± 0.93 0.56 ± 0.23 1.08 ± 0.58
Pro-inflammatory DC/Mϕ-derived IL-1β 1.09 ± 0.44 0.85 ± 0.40 1.67 ± 1.03
IL-23 0.45 ± 0.19 1.02 ± 0.56 1.71 ± 0.89
Protective Anti-inflammatory T cell factor IL-10 1.53 ± 0.81 0.62 ± 0.38 0.71 ± 0.35
Matrix metalloproteinase inhibitors TIMP1 1.31 ± 0.56 0.48 ± 0.23 0.85 ± 0.42
TIMP2 1.05 ± 0.39 0.50 ± 0.18 0.58 ± 0.25
TIMP3 0.77 ± 0.09 0.63 ± 0.15 0.70 ± 0.09
TIMP4 0.79 ± 0.19 0.97 ± 0.19 0.91 ± 0.22
Th1/Th2 transcription factors T-bet 1.75 ± 0.53 0.77 ± 0.11 0.84 ± 0.18
GATA3 1.87 ± 0.71 0.67 ± 0.27 0.69 ± 0.20
GM-CSF granulocyte macrophage colony-stimulating factor, IL interleukin, Th helper T cell
n = 6 mice/treatment group
ap ≤ 0.001 vs. anti-IL-17 + anti-GM-CSF (two-way analysis of variance and Bonferroni’s multiple-comparisons test)
bp ≤ 0.0001 vs. anti-GM-CSF
cp ≤ 0.0001 vs. anti-IL-17
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Fig. 3 (See legend on next page.)
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between GM-CSF and IL-23 in autoimmune inflammation
[18]. Interestingly, combined overexpression induced an
impressive increase in IL-23 on day 4, suggestive of a syn-
ergistic relationship (Fig. 4b). Although IL-17 or GM-CSF
alone induced increased IL-1β, receptor activator of nu-
clear factor κB ligand (RANKL) and MMPs, the combin-
ation additionally led to increased production of RANKL,
MMP9, MMP13 and S100A8 (Fig. 4b, c). Expression of
TIMP1 and TIMP2, but not of TIMP3 and TIMP4, was
increased in all groups (Fig. 4d).
Protein levels of IL-17 and GM-CSF were increased in
joint washouts after transfection with the respective vec-
tor or with both vectors (Fig. 5). Interestingly, although
the mRNA levels of IL-17 and GM-CSF were similar
(Fig. 4), we observed a 10-fold increase in GM-CSF over
IL-17 at the protein level, suggestive of increased transla-
tion, increased half-life or decreased consumption GM-
CSF. The effect of combined overexpression was most
noticeable in the production of IL-6, which showed a 10-
fold increase over the mice treated with Ad-IL-17 or Ad-
GM-CSF alone on day 4 (Fig. 5).
Discussion
GM-CSF has recently been identified as a key player in
Th17-mediated inflammation [16, 17, 23, 24]. Both GM-
CSF and IL-17 are produced by T cells and are critical
mediators of experimental arthritis [8, 13, 19, 23, 34, 35].
GM-CSF is essential for the pathogenicity of Th17 cells
and for the CCR4-dependent production of IL-23 by
DCs in EAE [16–18]. GM-CSF production by T cells is
regulated by the transcription factor NF-κB1 [23], as
well as by RORγt [16]. T cells lack GM-CSF receptors
[36], so the effect of T cell–derived GM-CSF on Th17-
mediated inflammation occurs via enhancement of IL-6
and IL-23 production from antigen-presenting cells [17].
IL-6 and IL-23 enhance GM-CSF production by T cells
by binding to the respective receptors, creating a positive
feedback loop [17]. In addition, IL-6 induces Th17 differ-
entiation in combination with IL-23 and tumour growth
factor β, creating a second feedback loop [37]. The close
relationship between GM-CSF and IL-17 in inflamma-
tory conditions suggests that therapeutic neutralisation
of one molecule might affect both molecules. Indeed,
prophylactic blockade of GM-CSF in IL-17 receptor-
deficient mice improved disease outcome in a model of
chronic relapsing arthritis [38]. The use of prophylactic
treatment and knockout mice in that study does limit its
clinical relevance, however.
In the present study, we show that combined thera-
peutic inhibition of IL-17 and GM-CSF significantly
improves the outcome of CIA in wild type mice over in-
hibition of these cytokines separately by targeting differ-
ent components of Th17-mediated joint inflammation.
IL-17 mediates chondrocyte metabolism and can induce
the expression of MMPs in synovial explants and fibro-
blasts [39, 40]. In primary cultures of human monocytes
and macrophages, IL-17 stimulated the production of
MMP9 [40]. In addition, IL-17 recruits neutrophils to
the joint, inhibits the synthesis of chondrocyte PGs and
induces the loss of PGs from mouse cartilage [11, 41].
We found that inhibition of IL-17 during established
arthritis caused only a modest decrease in the local ex-
pression of MMP3, MMP13 and IL-23, but a marked
reduction in systemic IL-6 levels, in accordance with
previous reports [12]. TNF could not be detected in
serum or joint washouts at the time of harvest, which
confirms earlier data from our laboratory showing that
TNF has an important role in the earlier stages of CIA
but is less involved in the late chronic phase of disease
[29, 30]. Anti-IL-17 did not prevent the influx of CD4+
T cells into the inflamed joints. This is in agreement
with our study in the mBSA/IL-1β model of acute
inflammatory arthritis, showing that it is the cytokine
milieu in the inflamed joint that promotes Th17 differ-
entiation from naive T cells in situ [8]. The beneficial ef-
fect of anti-IL-17 on joint pathology is therefore most
likely due to the direct blockade of neutrophil influx,
inhibition of Th17 differentiation and blockade of the
Th17 feedback loop by reducing the levels of IL-23 and
IL-6 in the synovium.
Anti-GM-CSF, either alone or in combination with
anti-IL-17, had a profound effect on the synovial expres-
sion of MMPs, with effects ranging from a reduction in
mRNA of 50 to 80 % (Table 1). This finding is in agree-
ment with the fact that the main producers of MMPs are
activated monocytes and macrophages [42], which depend
on GM-CSF for proliferation and differentiation [43].
IL-6 was reduced systemically in the serum by both
treatments; however, this reduction was not apparent in
washouts of joints. In fact, combination treatment led to
(See figure on previous page.)
Fig. 3 Histological analysis of joint damage after intraarticular injection of adenoviral vectors for interleukin (IL)-17 and granulocyte macrophage
colony-stimulating factor (GM-CSF). a Haematoxylin and eosin (H&E)- and Safranin O (SafO)-stained sections of knee joints on days 4 and 7 after
adenoviral transfer. E exudate, S synovitis, CD cartilage damage, B bone erosion, PG proteoglycan depletion. Representative sections are shown
from n = 6 joints/group. b Individual and c total histological scores for day 4 after adenoviral transfer. d Individual and e total histological scores
for day 7 after adenoviral transfer. Mean ± standard error of the mean for n = 6 joints per group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001;
analysis of variance followed by Bonferroni’s test for multiple comparisons
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Fig. 4 Quantitative PCR analysis of inflammatory and anti-inflammatory mediators in synovial tissue after adenoviral transfer into the knee joint.
a Interleukin (IL)-17, granulocyte macrophage colony-stimulating factor (GM-CSF), RAR-related orphan receptor γt (RORγt) and IL-23 expression in
synovial tissue determined at 4 h, day 1 and day 4 after adenoviral transfer. b Proinflammatory mediators IL-1β, receptor activator of nuclear factor κB
ligand (RANKL) and S100A8 expression in synovial tissue determined at 4 h, day 1 and day 4 after adenoviral transfer. c Matrix metalloproteinase (MMP)
expression in synovial tissue determined at 4 h, day 1 and day 4 after adenoviral transfer. d Expression of MMP inhibitors in synovial tissue determined
at 4 h, day 1 and day 4 after adenoviral transfer. n = 6 joints/group. Mean ± standard error of the mean. *p < 0.05, **p < 0.01 vs. Ad-IL-17; §p < 0.05,
¶p < 0.001, #p < 0.0001 vs. Ad-IL-17 + Ad-GM-CSF; analysis of variance followed by Bonferroni’s test for multiple comparisons. ADAMTS5 a disintegrin
and metalloproteinase with thrombospondin motifs, TF transcription factor, TIMP tissue inhibitor of matrix metalloproteinase
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an increase in the local level of IL-6 (Fig. 2a), and syn-
ovial tissue showed increased expression of IL-1β and
IL-23 in the absence of inflammation. The lack of acti-
vated T cells and the absence of inflammatory cells and
osteoclasts could account for the increase in IL-6 mea-
sured via reduced consumption [4, 28]. The increase in
IL-1β and IL-23 can be explained by increased local pro-
duction of IL-17, induced by formation of IL-17-anti-IL-
Fig. 5 Cytokine and chemokine analysis of joint washouts after adenoviral transfer into the knee joint. Luminex analysis for cytokines and
chemokines at 4 h, 1 day and 4 days after adenoviral transfer. a Interleukin (IL)-17. b Granulocyte macrophage colony-stimulating factor (GM-CSF).
c IL-1β. d IL-6. e CC chemokine ligand (CCL2). f CCL3. n = 6 mice per group. Mean ± standard error of the mean. ND not detected. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001; analysis of variance followed by Bonferroni’s test for multiple comparisons
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17 complexes or reduced consumption of these factors
owing to the almost complete absence of inflammatory
cells. In addition, mRNA levels were compared with
those of animals receiving control antibodies. Inflamma-
tion in those mice progressed to peak severity, and many
mice will be on the brink of disease remission owing to
the loss of cartilage and a lack of collagen (Fig. 1c).
The role of IL-17 and GM-CSF was confirmed by
overexpression of these cytokines in naive knee joints,
adding an additional strategy to study local interactions.
Intraarticularly injected adenoviral vectors preferentially
transfect fibroblasts and synoviocytes [26]. Previous stud-
ies showed that overexpression of IL-17 in joints of mice
during CIA increased bone erosion through the loss of the
RANKL–osteoprotegerin balance [44] and that IL-17 in-
duced MMPs only in the presence of TNF [29]. We found
that the main effects of IL-17 overexpression were inflam-
mation, PG depletion and bone erosion. We observed no
significant differences between IL-17 and GM-CSF over-
expression for any of the pathological features. By day 7,
both IL-17 and GM-CSF caused maximum inflammation.
Interestingly, although mRNA levels for IL-17 and GM-
CSF were similar after transfection with the respective
vectors (Fig. 4), the amount of GM-CSF protein measured
in the Ad-GM-CSF joint washouts was increased up to
10-fold compared with IL-17 in the Ad-IL-17 injected
joints. In addition, the level of GM-CSF remained high for
the duration of the experiment, whereas IL-17 levels de-
creased after day 4 (Fig. 5). Whether this was due to (1)
reduced IL-17 transcription by day 7, (2) a reduced half-
life of IL-17 compared with GM-CSF or (3) an increased
consumption of IL-17 is the subject of future investiga-
tion. Combined overexpression of IL-17 and GM-CSF led
to accelerated and more severe pathology, suggestive of
additive effects of these two cytokines. However, for the
production of IL-23, RANKL and MMPs, there was a
clear synergistic effect of IL-17 and GM-CSF. This was
partly mirrored by a marked reduction of RANKL and
MMPs after combined neutralisation, but, interestingly,
neutralisation led to a local increase in IL-1β and IL-23.
The absence of inflammation in the joints from animals
treated with the combination therapy results in a mark-
edly different composition of synovial cell populations,
which is reflected in the qPCR results. These discrepancies
may be resolved in future experiments either by standar-
dising RNA levels to the expression of cell-specific
markers (such as CD4) to correct for the difference in cell
number or by analysing specific cell populations by flow
cytometry rather than by qPCR.
Conclusions
Overall, our results illustrate that complex interactions
exist between IL-17 and GM-CSF during inflammation.
Blockade of one of these cytokines can take away
additive effects, but it does not by definition inhibit the
other cytokine. Therefore, blocking both IL-17 and GM-
CSF has an advantage over single-molecule inhibition. In
view of the introduction of IL-17 and GM-CSF inhibitors
in the clinic for autoinflammatory conditions such as RA
and multiple sclerosis (recently reviewed in [4, 45, 46]),
this is an important observation. Some patients do not re-
spond to therapeutic inhibition, such as with TNF inhibi-
tors [47]. On the basis of the additive beneficial effect of
IL-17 and GM-CSF inhibition during CIA, combination
therapy could greatly benefit this group of patients.
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